

FY2021 Full-Year Financial Results Briefing for Institutional Investors

YCP Holdings (Global) Limited February 2022



Introduction

FY 2021 Financial Highlights

FY 2021 Business Results for Management Services

FY 2021 Business Results for Principal Investment

Forecast for FY2022

FY2022 Business Plan and Growth Strategy

Appendix

Introduction



Company Overview Introduction



YCP Group started its business in August 2011 as Yamato Capital Partners (now YCP Solidiance). In 2013, in order to actively hire non-Japanese professionals and be an international organization, the firm name was changed to YCP, and it became a Hong Kongbased holdings company. In 2021, the Group moved its headquarters to Singapore, where it is advantaged as a global hub site; the Group's revenue and personnel composition has increased, and established YCP Holdings (Global) Limited as the holding company.

An Overview of YCP Group


Company Name	YCP Holdings (Global) Limited	Asia (15 offices)	Japan Shanghai
Headquarters	3 Fraser Street, DUO Tower #05-21, Singapore	UAE	India Hong Kong Myanmar Taiwan
Nature of Business	 Management Services Principal Investment 	Number of Professionals by Region Japan : 63 Southeast Asia : 114 Greater China : 39 Middle East / India : 18	Philippines Thailand Vietnam Malaysia Jakarta, Indonesia (Digital Studio)
Year of Founding	August 2011		
Capital	USD 38,305,713	Middle East / India : 18 Europe EU : 2	USA USA: 2
Group CEO	Yuki Ishida	Amsterdam	USA
Number of employees*1	Number of professionals: 238 Total number of including portfolio companies: 437 021: the number of professionals by region is the total number of people in the Managem		

*2: Number of offices is as of the date of submission of this document.

Global Locations*2



Our group operates two businesses: 1) Management Services, which helps our clients grow, scale, and transform their businesses, and 2) Principal Investment, which provides risk-money via equity capital and support for our portfolio companies. We accelerate the growth of both our Management Services and Principal Investments businesses through three core strengths: cross-border business development through our global network, M&A expertise, and our focus on digital transformation.



FY 2021 Financial Highlights



Summary FY2021 Financial Highlights



FY2021 Financial Results

Revenue	YoY	Progress Rate
73.1 million USD (8.41 billion JPY*)	+24.1%	<i>102.1</i> %
Operating Profit	YoY	Progress Rate
7.9 million USD (905 million JPY*)	-4.3 %	<i>103.4</i> %
Profit for the Period	YoY	Progress Rate
5.0 million USD (574 million JPY*)	-23.4%	90.6 %

Highlights

- Revenue and operating profit were both over the budget.
- In the core Management Services business, there was +16.7% revenue growth and +20.4% profit growth due to continuous PMO needs in M&A and DX implementation throughout Asia.
- In the Principal Investment business, although profit decreased due to the impact of one-time gains in FY20 that did not occur in FY21—such as valuation gains on an equity investment (USD 0.8 million) and bargain purchase gains on acquisitions (USD 1.6 million)—the business remained profitable and continued to make aggressive investments to achieve sales growth.
- One-time administrative expenses associated with the IPO in FY21 of approximately USD 1.2 million also contributed to lower earnings.
- As for the profit, the effective tax rate on a consolidated basis worsened compared to the budget and the progress rate was only 90.6%, because subsidiaries with large tax burdens increased profits, while subsidiaries with small tax burdens incurred losses.

* Conversion to Japanese yen is calculated based on 1US\$ = 115.02 yen (exchange rate on 30 December 2021)



Management Services achieved YoY+16.7% revenue growth and +20.4% operating profit growth. Principal Investment achieved significant growth of YoY+33.2% in revenue thanks to the past aggressive investment. Operating profit declined due to additional IPO costs of USD 1.2 million, while the firm achieved CAGR of 26.4% in the most 5 recent fiscal years.

Revenue and Operating Profit (USD million) Segment Profit/Loss (USD million) Management Services Firmwide Management Services CAGR26.4 % Principal Investment 73.1 +24.1%Principal Investment Management --- Operating Profit Corporate and Unallocated Expenses Services 58.9 Principal +20.4%50.6 11.1 35.3 Investment 9.2 40.4 +33.2% 26.5 20.1 29.8 Principal 19.5 37.8 5.5 22.7 Investment Management 32.4 16.5 - 55.0% Services 30.5 13.3 2.3 8.2 7.9 +16.7% 20.9 1.0 1.5 13.3 0.0 9.4 -2.9 -3.3 -4.2 FY2019 FY2020 FY2021 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021


FY 2021 Business Results for Management Services






YCP Solidiance, a wholly owned subsidiary of YCP Group, offers our core business of Management Services. It provides mainly PMO-type execution support services such as M&A and DX implementation for clients.

Revenue Composition by Deal Type* (%)



The majority of our projects are on-site resident PMO projects related to M&A and DX implementation. We are able to build long-term relationships with our clients over several years and accumulate projects on an ongoing basis. * Actual for the period of January – October 2021

PMO Support in M&A



We begin providing support from one month prior to M&A execution, and continue to provide long-term support via our PMO.



Revenue increased in all regions, except for Greater China, where revenue declined due to a reduction in the workforce caused by the COVID-19 pandemic. However, operating profit also increased, maintaining a high profit margin.

KPI

Overall Japan Revenue Southeast Asia 51 49 45 44 37.8 **+16.7%** Greater China Others Japan 34 33 34 33 3.7 28 26 32.4 ----Segment profit/loss 30.5 **Overseas** 2.7 6.0 Overseas Ratio 3.5 Sales 87 83 6.3 76 48% 76 77 76 76 74 71 5.6 20.9 Southeast Asia 6.5 5.6 19.7 13.3 Domest 17.0 Sales 15.9 47 9.4 +16% 39 35 36 2911.1 Greater 27 26 24 9.2 China 29 19 15 9 5.5 **O**2 **Q**1 **O**2 Q3 Q1 **Q**3 **O**4 **O**4 Jan. FY2018 FY2019 FY2020 FY2021 FY2016 FY2017 **FY22 FY20 FY21** *1: Number of full-time employees in the Management Services Division as of the end of each fiscal year (excluding the Operations Division) *2: Net sales in the management services business for each period divided by the average number of employees during the period, including subcontractors (excluding the Operations Division)

Revenue and Segment Profit/Loss (USD million)

FY 2021 Business Results for Principal Investment






Utilizing the professional platform cultivated through the management service business, we invest our own funds in small and medium-sized emerging companies. Currently, we continue to make long-term investments in personal care and pet care as focus industries, and are also actively investing in business seeds as strategic investment which will become a focus industry in the future.

Investment Requirements

The following 5 criteria are set as investment requirements:

- 1. Expected business scale of USD 100 million or more in sales
- 2. A business that can expand globally and utilize the Group's professional platform
- 3. Investment size should not exceed USD 20 million, including debt.
- 4. Minimum 30% IRR (Internal Rate of Return).
- 5. Good learning opportunity for the Group's professionals to achieve "Strive for Growth"

Flow of Principal Investment, from Start-up to Expansion






Performance (USD million)

SOLIA, a major consolidated subsidiary, develops brands specializing in personal care products throughout Asia. In FY 2021, a new brand was successfully launched which contributed to achieving higher YoY revenue and profits.

Business Overview





Performance (USD million)

FY17

FY16


FY18

FY19



YCP Lifemate, a major consolidated subsidiary, runs our businesses in the pet care field acquired mainly through M&A. It achieved a significant increase in sales through succession of a large-scale veterinary hospital, and is now currently operating five hospitals.

Business Overview



management reforms through business succession. By grouping multiple hospitals together through M&A, we aim to create synergy through common and efficient management functions, improve working environments through interhospital cooperation, and eventually scale up the overall business.

FY21

FY20

Strategic Investments FY 2021 Business Results for Principal Investment




We continued to actively invest in business seeds as strategic investment on what we target to grow into a focus industry in the future. The current portfolios include Japanese F&B business in Singapore and Hong Kong, and services for seniors in Japan. In FY2021, the revenue increased due to the gradual recovery of the F&B business as a result of the relaxation of COVID-19 restrictions. On the other hand, profit decreased due to one-time, non-cash items such as fair value of gain(loss) on equity investment (FY2021: USD -0.1 million, FY2020:USD 0.8 million)*1, gain on bargain purchase (FY2020: USD 1.6 million)*2, and impairment on F&B businesses (FY2021: USD -0.3 million) due to the Omicron outbreak in Hong Kong.

Business Overview



With the mission to "bring smiles to people's faces around the world through food," the company is optimizing the cooking process and thoroughly improving operational efficiency to develop highquality Japanese food brands overseas. We are engaged in the business of "auto-transportation" cemeteries. There is a serious shortage in urban areas of resting places for the deceased due to a rapidly aging population and increasing demand for funeral services. We offer a new option that requires no management, no successor, and no religious affiliation. Currently, we have two ossuaries in Tokyo.

Performance (USD million)



*1: Gains on valuation of financial assets at fair value through profit or loss related to shareholdings in ipet Insurance Co., Ltd. (ipet Holdings Company Limited from 1 October 2020). 0.8 million USD in FY2020 and 0.1 million USD in FY 2021

*2: Gain on bargain purchase related to the acquisition of J-Foods (FY2020: USD 1.6 million)


Forecast for FY2022



Consolidated Financial Forecast Forecast for FY2022



Given the intensifying competition for human resources in Japan and overseas, for FY 2022 we conservatively forecast revenue to increase by YoY +8.9%. Operating profit is forecasted to increase by YoY+23.1% due to the absence of one-time IPO costs of USD 1.2 million, which was incurred in FY2021.






In FY2022, we expect revenue to increase by YoY +9.6% and operating profit to decrease by -7.0%. Operating profit is expected to decrease due to the conservative forecast for FY2022. While FY2021 was higher than the initial forecast, we will consider revising the forecast based on the progress through H1 (up to Q2) of FY2022.


Basis for Formulation

Forecast (USD million)





For FY2022, we expect overall Principal Investment revenue to increase by YoY +8.2% and operating profit to increase by YoY +114.4%. Forecasts for each segment are as follows:



- Expect to expand earnings by aggressively investing in advertising for new domestic brands and strengthening overseas sales of ALOBABY
- Operating profit expected to decline slightly in FY2022 due to one-time subsidy of USD 0.3 million in FY2021

Basis for


Formulation

- Revenue is expected to increase at each existing hospital as the impact of the COVID-19 pandemic lessens
- In addition, the succession of a new veterinary hospital is expected to contribute to revenue
- Revenue and earnings are expected to remain flat, as no major investments or new business developments have been factored into the plan for FY2022
- On the other hand, we expect a significant improvement in profitability in the F&B business due to further relaxation of COVID-19 regulations.

FY2022 Business Plan and Growth Strategy

Growth Strategy for the Entire Group FY2022 Business Plan and Growth Strategy







In addition to organic business expansion through continuous expansion of the organization, we aim to achieve exponential growth through the acquisition of local firms in India and China and the productization of services for B2B.

Organic Growth




- Demand for PMO support for M&A and DX implementation—which accounts for the majority of revenue—is strong, and the company is targeting organic annual revenue growth of 15% in Japan, 30% overseas, and about 20% for the overall Group in comparison to the previous fiscal year.
- In addition, we expect annual unit price improvement in overseas markets to be about 10% from the previous fiscal year.
- We also aim to continuously increase the number of professionals*, both in Japan and overseas, with a target of 235 professionals by 2023.

Exponential growth through M&A



- Integration with Solidiance Asia Pacific Pte. Ltd. in 2018 led to rapid expansion of Management Services (sales growth of 157% in FY2018 and 146% in FY19).
- We are considering M&A of local boutique firms to strengthen our presence in India and China, both of which are large markets.

X Scale through Productization




- Of the various service lineups currently offered, services such as DX solutions and Market Research will be standardized and incorporated into highly versatile products.
- We aim to promote external sales of standardized products by the middle office, with the aim to scale as a peripheral business to Management Services.

* Number of full-time employees in the Management Services Division as of the end of each fiscal year (excluding the Operations Division)




Most of the funds raised through this listing will be invested in Personal Care and Pet Care, the focus industries of Principal Investment. In the long term, we aim to list each of them independently, raise additional funds, and reinvest in Management Services and new business seeds to accelerate the growth of the entire group.

Personal Care



Pet Care




- In addition to the cash generated by its main brand, ALOBABY, we will also utilize the funds raised through the listing and continue to aggressively invest in advertising, aiming to scale up the revenue.
- We aim to strengthen sales of ALOBABY overseas, particularly in China. In Japan, we aim to launch new brands such as HALENA and AMBIQUE by expanding its customer base, especially through the fast-growing EC channel, and by increasing the number of repeat customers on its official website.
- Continue to aggressively promote the succession of large hospitals at one or two hospitals each year using the funds raised, and further generating synergy among hospitals.
- In addition to improving operational efficiency through DX at the succeeding hospitals, we will actively invest in digital marketing and other advertising methods to increase the number of new patients and further strengthen the profitability of each hospital.







About JDR (Japanese Depositary Receipt)



* Cited from the JDR issuance scheme (example) on the Japan Exchange Group website: https://www.jpx.co.jp/equities/listing-on-tse/new/basic/05.html

